Product Description: RIPK2-IN-7 (Compound 10w) is an orally active, selective RIPK2 inhibitor (IC50: 0.6 nM). RIPK2-IN-7 inhibits RIPK2 kinase activity, blocks the nucleotide-binding oligomerization domain (NOD) signaling pathway, and reduces the production of inflammatory factors (such as TNFα). RIPK2-IN-7 can be used in the study of inflammatory bowel disease (IBD)[1].
Applications: COVID-19-immunoregulation
Formula: C19H22FN5
References: [1]Yuan X, et al. Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs). J Med Chem. 2022 Jul 14;65(13):9312-9327.
CAS Number: 2789711-40-4
Molecular Weight: 339.41
Research Area: Inflammation/Immunology
Target: NOD-like Receptor (NLR);RIP kinase;TNF Receptor